Greetings #RheumJC friends!
First, we have an exciting announcement: We’ve teamed up with Healio Rheumatology, who is going to be helping the #RheumJC team with summaries of articles, graphics, and helping to expand the reach of our journal club. We’re greatly looking forward to working with them!
Our next journal club will be Thursday, February 27th at 9pm Eastern Time / 8pm Central Time (click here to find this in your local time zone).
We’re going to be discussing the two articles reporting results from the TULIP–1 and TULIP–2 trials, which looked at the use of the type I interferon receptor blocker anifrolumab in systemic lupus erythematosis.
TULIP–1
– Healio Rheumatology Summary
– The Lancet Rheumatology: Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP–1): a randomised, controlled, phase 3 trial
TULIP–2
– Healio Rheumatology Summary
– NEJM: Trial of Anifrolumab in Active Systemic Lupus Erythematosus
If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.
As always:
- Please remember to try to stay on topic whenever possible.
- Be polite and courteous.
- Do not violate HIPAA.
We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.